HUMA News and Press, Humacyte Inc. From 12/01/22

DURHAM, N.C., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues and advanced tissue constructs and organ systems at commercial scale, today announced presentations on the ...

DURHAM, N.C., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief E...

Humacyte, Inc. (HUMA) Q3 2022 Earnings Conference Call November 10, 2022 08:00 AM ET Company Participants Lauren Marek - LifeSci Advisors, IR Laura Niklason - President & CEO Dale Sander - CFO & Chief Corporate Development Officer Conference Call Pa...

Humacyte press release ( NASDAQ: HUMA ): Q3 GAAP EPS of -$0.25 misses by $0.04 . Revenue of $0.03M (-87.5% Y/Y) misses by $0.17M . For further details see: Humacyte GAAP EPS of -$0.25 misses by $0.04, revenue of $0.03M misses by $0.17M

-- Progress Continues in Clinical Development of Human Acellular Vessel™ (HAV™) for Vascular Trauma; BLA Filing Anticipated mid 2023 – -- Experience with HAV in Ukrainian War Vascular Trauma Mirrors Clinical Experiences in Civilians in the U.S., High Patency...

Humacyte ( NASDAQ: HUMA ) is scheduled to announce Q3 earnings results on Thursday, November 10th, before market open. The consensus EPS Estimate is -$0.22 (+69.4% Y/Y) and the consensus Revenue Estimate is $0.2M (-16.7% Y/Y). Over the last 3 months, EPS estimates have...

Six-month primate HAV CABG model demonstrates patency, recellularization and remodeling resembling native blood vessels HAV may address many limitations of current standard of care grafts used in CABG procedure DURHAM, N.C., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc....

DURHAM, N.C., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue, complex tissue systems, and organs at commercial scale, will release its financial results for the th...

Summary Shares of tissue regeneration firm Humacyte, Inc. are down over 70% from their opening trade post-SPAC merger in August 2021, dogged by a lack of news and slow trial enrollments. Those dynamics should change as Phase 3 data from its human acellular vessel candidate in the ...

DURHAM, N.C., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues, complex tissue systems, and organs at commercial scale, today announced the presentation of a clini...